Abstract
4P IgM-rheumatoid factor as a novel biomarker for a reduced survival in anti-PD-1 treated NSCLC patients through the decrease of CD137+ T-cells
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have